Earnings Releases·Nov 5, 2026, 4:07 PM ET

Ginkgo Bioworks — Third Quarter 2026 Earnings Summary

Q3 2026 revenue was $28 million (down 6% YoY, up from $20 million in Q2), while GAAP net loss narrowed to $41 million from $73 million YoY and Adjusted EBITDA improved to ($22) million from ($53) million.
Full-year 2026 cash burn guidance remains reaffirmed at ($125) to ($150) million, with Q3 cash burn at $27 million and year-to-date revenue declining to $67.3 million from $106.7 million.
Strategic momentum includes new customer wins such as a Novo autonomous lab sale, a $17.5 million ARPA-H subcontract, and 22 ADME-One customers, alongside government recognition of autonomous labs as national infrastructure.
Liquidity position stands at $285 million in cash and marketable securities as of September 30, 2026, though total stockholders' equity decreased to $392.6 million from $508.6 million at the start of the year.